The role of checkpoint inhibitors in classical Hodgkin lymphoma

0 Views

06/26/23

Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, describes the efficacy of checkpoint inhibitors in treating classical Hodgkin lymphoma, which is the current standard of care in patients who have progressed from autologous stem cell transplantation. Multiple trials have demonstrated durable responses in patients receiving checkpoint inhibitors such as pembrolizumab with ICE or GVD chemotherapy and nivolumab with brentuximab vedotin as a salvage regimens. Further research will additionally reveal the potential of checkpoint inhibitors in the frontline setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.